Definitive Healthcare Corp (DH)vsJohnson & Johnson (JNJ)
DH
Definitive Healthcare Corp
$1.26
-3.82%
HEALTHCARE · Cap: $140.38M
JNJ
Johnson & Johnson
$282.84
-1.12%
HEALTHCARE · Cap: $682.52B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 43601% more annual revenue ($99.33B vs $227.31M). JNJ leads profitability with a 16.2% profit margin vs -69.2%. JNJ earns a higher WallStSmart Score of 54/100 (C-).
DH
Hold37
out of 100
Grade: F
JNJ
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+74.6%
Fair Value
$6.66
Current Price
$1.26
$5.40 discount
Intrinsic value data unavailable for JNJ.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 26.6%
Generating 6.4B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -116.5% — below average capital efficiency
Revenue declined 9.0%
Trading at 8.4x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : DH
The strongest argument for DH centers on Price/Book, Debt/Equity.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 26.6%.
Bear Case : DH
The primary concerns for DH are EPS Growth, Market Cap, Return on Equity.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 43.0x leaves little room for execution misses.
Key Dynamics to Monitor
DH profiles as a turnaround stock while JNJ is a mature play — different risk/reward profiles.
DH carries more volatility with a beta of 1.36 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (54/100 vs 37/100), backed by strong 16.2% margins. DH offers better value entry with a 74.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Definitive Healthcare Corp
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Definitive Healthcare Corp (DH) is a leading provider of comprehensive data and analytics solutions designed specifically for the healthcare industry, catering to a diverse clientele that includes pharmaceutical companies, payers, and healthcare providers. By harnessing extensive datasets and cutting-edge real-time analytics, Definitive Healthcare enhances operational efficiencies and delivers critical strategic insights, ultimately improving patient outcomes. With a strong commitment to innovation, the company is well-positioned to capitalize on the growing demand for sophisticated healthcare analytics, thereby establishing itself as a pivotal player in the transformation of healthcare delivery.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other HEALTH INFORMATION SERVICES Stocks
Want to dig deeper into these stocks?